Clinilabs Completes Routine FDA Inspection with No Observations
Wednesday, April 15, 2026
Clinilabs LLC, a global full-service contract research organisation (CRO) focused on the development of medicines and medical devices for the central nervous system, has successfully completed a routine inspection by the US Food and Drug Administration (FDA) with no observations.
The outcome highlights the company’s continued commitment to maintaining high standards in regulatory compliance, operational performance and patient safety across its clinical research programmes.
The announcement also noted that the original version of the statement remains the legally valid document, while translations are provided for reference only.
Source: businesswire.com
